Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.67)
# 4,115
Out of 5,135 analysts
57
Total ratings
31.25%
Success rate
-29.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKTX Akari Therapeutics, | Initiates: Buy | $1 | $0.24 | +316.67% | 1 | Jan 5, 2026 | |
| ARDX Ardelyx | Assumes: Buy | $11 | $6.72 | +63.69% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $22.27 | +39.20% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.50 | +1,166.67% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $18.09 | +16.09% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $6.47 | -22.72% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.59 | +906.29% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $0.75 | +15,897.87% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $25.53 | -2.08% | 2 | May 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $53.48 | - | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,000 | $1.25 | +159,900.00% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.07 | +554.21% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $6.21 | +61.03% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $11.46 | +423.56% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.05 | +471.43% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.41 | +193.26% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.69 | +14,101.18% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $2.37 | +7,579.32% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $4,500 → $2,000 | $2.31 | +86,480.09% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $12.94 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.90 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.48 | +1,150.00% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $8.66 | +142.49% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $9.47 | +110,776.45% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.43 | +1,422.63% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $73.18 | +309.95% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $792.16 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $102.99 | -13.58% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $128.38 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.67 | +20,019.76% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.34 | +438.92% | 1 | Mar 19, 2020 |
Akari Therapeutics,
Jan 5, 2026
Initiates: Buy
Price Target: $1
Current: $0.24
Upside: +316.67%
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $6.72
Upside: +63.69%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $22.27
Upside: +39.20%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.50
Upside: +1,166.67%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $18.09
Upside: +16.09%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $6.47
Upside: -22.72%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.59
Upside: +906.29%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $0.75
Upside: +15,897.87%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $25.53
Upside: -2.08%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $53.48
Upside: -
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $1.25
Upside: +159,900.00%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.07
Upside: +554.21%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $6.21
Upside: +61.03%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $11.46
Upside: +423.56%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.05
Upside: +471.43%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.41
Upside: +193.26%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.69
Upside: +14,101.18%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $2.37
Upside: +7,579.32%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $4,500 → $2,000
Current: $2.31
Upside: +86,480.09%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $12.94
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.90
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $0.48
Upside: +1,150.00%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $8.66
Upside: +142.49%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $9.47
Upside: +110,776.45%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.43
Upside: +1,422.63%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $73.18
Upside: +309.95%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $792.16
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $102.99
Upside: -13.58%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $128.38
Upside: -
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.67
Upside: +20,019.76%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.34
Upside: +438.92%